Novo Nordisk's Mixed Bag: Zenagamtide Data Delights, CagriSema Stumbles, Veru Deal Emerges

Novo Nordisk stock fell 4.4% on CagriSema's weight loss gap vs Lilly; Zenagamtide slashed HbA1c 1.71% in Phase 2; Veru partnership and buyback offer support.

For Novo Nordisk, the parade of pipeline news at the American Diabetes Association meeting in New Orleans delivered a classic tale of two drugs — one offering genuine hope, the other deepening a competitive wound. The stock closed the week at €37.35, down roughly 4.4% over the past seven days, and more than 41% below the high it touched in June 2025.

If there was a clear bright spot, it came from zenagamtide — the internal candidate also known as amycretin. This unimolecular peptide agonist targets both GLP-1 and amylin receptors in a single molecule. In a Phase 2 trial involving type 2 diabetes patients, the highest 40 mg dose slashed HbA1c by an average of 1.71 percentage points over 36 weeks. Nearly 89% of participants in that cohort hit the clinically meaningful target of HbA1c below 7%, while body weight dropped 14.6%. Novo Nordisk plans to kick off a Phase 3 program for type 2 diabetes in the second half of 2026.

The CagriSema story, however, remained a tougher sell. The fixed combination of the amylin analogue cagrilintide and semaglutide achieved a 23% weight reduction after 84 weeks in the head-to-head REDEFINE-4 study. But Eli Lilly's Zepbound (tirzepatide) delivered 25.5% — a gap that has weighed on the stock for months and crystallizes exactly why the market remains skeptical. An FDA decision on CagriSema for weight management is expected in the second half of 2026, while a higher-dose version has yet to enter Phase 3.

Beyond the conference floor, Novo Nordisk quietly advanced a novel partnership. A SEC filing by U.S. biotech Veru Inc. revealed a clinical supply agreement: Veru is testing the oral agent enobosarm — a selective androgen receptor modulator — in combination with Wegovy (semaglutide) in its Phase 2b PLATEAU study targeting older obese patients. Novo Nordisk provides Wegovy at no cost, securing negotiation rights for future commercial GLP-1 combination products. The market reacted instantly: Veru shares surged 167% on the day of the announcement, while Novo Nordisk gained about 4% on Thursday — not enough to offset earlier losses for the week.

Two early-stage programs have also quietly entered the clinic. NNC0497-0040 began a randomized, quadruple-blind Phase 1 trial in May 2026 and is still recruiting participants. A second candidate, the injectable obesity drug NNC0113-5840, was filed in April and is also enrolling. Both remain in the earliest safety phase, with clinically meaningful results far off.

In the background, a hefty buyback program offers mechanical support. Since February 4, Novo Nordisk has repurchased roughly 17.9 million B-shares at an average price of 263.47 Danish kroner, spending around 4.7 billion kroner. The overall program is authorized for up to 15 billion kroner over twelve months, through February 2027.

Analysts remain cautious. Among 23 brokerages covering the stock, 18 rate it a "hold," four a "buy," and one a "sell." The average price target stands at 311.80 Danish kroner, well above current levels, but the range from a pessimistic 200 to an optimistic 454 kroner underscores the deep uncertainty. Goldman Sachs reaffirmed its "hold" rating in early June. Key concerns include U.S. pricing pressure on Wegovy, the rollout of oral semaglutide in international markets, and the competitive threat from Lilly's tirzepatide.

The stock has recovered about 23% from its March low of €30.25, now trading above its 50-day moving average of €35.80. Still, it sits roughly 10% below the 200-day average of €41.67 and nearly 47% below the year's peak. Novo Nordisk itself forecasts a 5–13% decline in sales and operating profit for 2026, driven by expiring semaglutide exclusivities in several markets and U.S. pricing headwinds.

Investors will get more clarity soon. An R&D investor day is scheduled for Sunday, June 7 at 6:30 p.m. CDT, where management will chew over the week's clinical data. The half-year results land on August 5, followed by a Capital Markets Day on September 21.